Market Overview
Biomarker testing services involve the analytical and clinical laboratory work required to detect and quantify molecular, cellular, protein, and genetic indicators of disease or therapeutic response. The market is valued at around $19.75 billion in 2025 and is forecast to reach roughly $22.26 billion by the end of the decade on a 3.04% CAGR. Demand is anchored by healthcare providers, pharmaceutical companies, and research institutions that rely on biomarker data for clinical decision-making and drug development.
- •2025 market value of approximately $19.75 billion with a 3.04% CAGR through 2030.
- •Core service offerings include assay development, flow cytometry, genetic and genomic testing, and protein-based analysis.
- •End users span hospitals, clinical laboratories, pharmaceutical and biotechnology firms, and academic research centers.
Growth Drivers
The principal growth driver is the accelerating shift toward personalized medicine, where biomarker tests are essential for selecting targeted therapies and monitoring patient response. Rising global incidence of cancer, cardiovascular disease, and neurological disorders is expanding the clinical addressable population for biomarker-based diagnostics. Companion diagnostic development tied to new drug launches is also creating sustained demand for specialized testing services.
- •Personalized medicine and targeted therapy adoption continue to widen the use of biomarker assays.
- •Growing cancer and chronic disease burden increases screening, diagnostic, and monitoring test volumes.
- •Regulatory approvals of companion diagnostics create recurring service demand from pharmaceutical sponsors.
Segmentation and Regional Analysis
The market is segmented by service type into categories such as biomarker assay development, flow cytometry, genomic and genetic testing, and protein biomarker analysis, with assay development and molecular testing representing the largest revenue contributors. By end user, the pharmaceutical and biotechnology segment holds significant share due to extensive use in clinical trials and drug development, while hospital and clinical laboratories lead in patient testing volume. Geographically, North America dominates the market, supported by advanced healthcare infrastructure, high R&D spending, and a concentration of diagnostic companies.
- •Service segmentation spans assay development, flow cytometry, genomics, proteomics, and related specialty testing.
- •North America leads in revenue share, followed by Europe and the Asia-Pacific region.
- •Pharmaceutical and biotechnology sponsors represent the fastest-growing end-user segment for biomarker services.
Trends and Outlook
What are the recent trends and outlook?
Key trends shaping the market include the integration of multi-omics approaches, expansion of liquid biopsy and circulating biomarker testing, and growing use of artificial intelligence in biomarker data interpretation. Liquid biopsy in particular is gaining traction in oncology for non-invasive tumor profiling and treatment monitoring. Looking ahead, the market is expected to maintain steady growth as biomarker testing becomes more deeply embedded in routine clinical practice and drug development pipelines.
- •Liquid biopsy and circulating tumor DNA testing are among the fastest-growing service categories.
- •AI and bioinformatics tools are increasingly used to interpret complex biomarker datasets.
- •Continued expansion of companion diagnostic programs is expected to underpin long-term service demand.
Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.
Connect to an analyst →Market size and forecast are Claight Analysis, informed by public research and industry data. Historical years before 2025 and all forecast years are Claight estimates at the stated CAGR. Retrieved 2026.